# Odyssey Health, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Odyssey Health, Inc.). ## Overview Odyssey Health, Inc. is a Nevada-based medical product development company focused on acquiring, licensing, and advancing healthcare technologies through its operating subsidiaries. Its reported pipeline includes the CardioMap heart monitoring and screening device and the Save-A-Life choking rescue device, with development and commercialization intended to occur through third-party partners and distributors. ## Products & services • CardioMap heart monitoring and screening device • Save-A-Life choking rescue device • Medical product development and licensing • Third-party manufacturing and distribution partnerships • Intellectual property acquisition and commercialization - **CardioMap device** (40%) — Heart monitoring and screening technology under development for medical use. - **Save-A-Life device** (40%) — Choking rescue device designed for emergency response and airway obstruction use. - **Licensing and distribution rights** (15%) — Potential license fees, royalties, and distribution agreements for approved products. - **Medical technology acquisition** (5%) — Acquisition of medical products, assets, and intellectual property for development. - CardioMap heart monitoring and screening device - Save-A-Life choking rescue device - Medical product development and licensing - Third-party manufacturing and distribution partnerships - Intellectual property acquisition and commercialization ## Customers Odyssey Health’s end customers are expected to be healthcare providers, distributors, and commercial partners that market approved medical devices. The company’s products are aimed at clinical and emergency-use settings, while its monetization model also depends on licensing partners and distributors that can commercialize the technologies. Because the products are still in development, customer demand is tied to regulatory clearance and partner adoption rather than direct sales today. - **Healthcare providers** (primary) — Hospitals, clinics, and care settings that would buy or use approved monitoring and rescue devices. - **Medical device distributors** (primary) — Third-party distributors that sell the company’s products and provide market access. - **Licensing partners** (primary) — Commercial partners that pay upfront fees and royalties to market or sublicense products. - **Emergency-use end users** (secondary) — Users and institutions that need choking rescue tools for rapid response situations. - Hospitals and clinics that may use CardioMap for screening - Emergency and first-aid users for choking rescue devices - Medical device distributors that commercialize approved products - Licensing partners that pay fees and royalties - Potential international channel partners for market access ## Geography Odyssey Health is headquartered in Las Vegas, Nevada, and is organized as a U.S. public company with subsidiaries in the United States and Australia. The business is intended to commercialize products in the United States and internationally through licensing and distribution agreements, so future revenue exposure is expected to depend on regulatory approvals and partner networks across multiple markets. - Headquartered in Las Vegas, Nevada - U.S. corporate base and primary regulatory home market - Australia subsidiary supports international structure - Planned commercialization in the United States and abroad - International licensing is part of the growth model ## Strategy The company’s strategy is to acquire or develop medical technologies, secure regulatory clearance, and then commercialize them through distributors or licensing partners. It also seeks to expand the addressable market by pursuing additional uses for CardioMap and by building an intellectual-property portfolio that can support future product lines and royalty streams. - **Obtain regulatory clearance for product candidates** (short-term) — Commercial sales depend on FDA or other regulatory approval. - **Build distribution and licensing partnerships** (short-term) — Third-party channels are intended to accelerate market entry and revenue generation. - **Broaden the technology platform** (medium-term) — Additional uses can increase the commercial value of the core technology base. - Advance CardioMap and Save-A-Life toward regulatory approval - Use distributors and licensees to reach market faster - Pursue international licensing opportunities - Expand CardioMap into additional medical applications - Acquire technologies and IP with commercial potential ## Risks Odyssey Health faces the typical risks of an early-stage medical device developer, including regulatory approval risk, clinical and product-development uncertainty, and dependence on third-party commercialization partners. Because it currently has no marketed products, execution risk is concentrated in funding, intellectual property protection, and the ability to build a viable distribution network after approval. - **Regulatory approval risk** [critical] — Product candidates cannot be sold commercially until cleared or approved by regulators. - **Distribution network risk** [high] — The company expects third parties to market and sell products, which may not materialize or perform well. - **Funding and going-concern risk** [high] — Development-stage operations require external capital before product revenue exists. - **Intellectual property risk** [high] — The business depends on patents, trademarks, and proprietary technology to protect value. - No approved products yet, so revenue depends on future clearance - FDA and other regulatory outcomes may delay or block commercialization - Distributor dependence can limit control over sales execution - Intellectual property disputes could weaken product protection - Limited operating history increases financing and execution risk ## Accounting The most important accounting issue is the absence of product revenue, which makes operating results highly dependent on development, general and administrative, and stock-based compensation expenses. Investors should also watch estimates around going concern, debt and interest expense, and any future valuation or impairment judgments tied to acquired technologies and intangible assets. - **Going concern assessment** — Affects investor assessment of solvency and capital needs - **Stock-based compensation** — Affects operating loss and dilution analysis - **Debt and interest expense** — Affects net loss and cash flow interpretation - **Intangible asset valuation and impairment** — Could materially affect balance sheet and earnings - No revenue yet, so expense timing drives reported losses - Stock-based compensation can materially affect operating results - Going-concern disclosures signal financing dependence - Debt and interest expense affect cash burn and dilution analysis - Future acquired IP may require valuation and impairment testing --- *Last updated: 2026-04-29T04:43:36.955624+00:00*